995 related articles for article (PubMed ID: 18687639)
1. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
Gutiérrez OM; Mannstadt M; Isakova T; Rauh-Hain JA; Tamez H; Shah A; Smith K; Lee H; Thadhani R; Jüppner H; Wolf M
N Engl J Med; 2008 Aug; 359(6):584-92. PubMed ID: 18687639
[TBL] [Abstract][Full Text] [Related]
2. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2009 Sep; 24(9):2792-6. PubMed ID: 19395730
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
Isakova T; Xie H; Yang W; Xie D; Anderson AH; Scialla J; Wahl P; Gutiérrez OM; Steigerwalt S; He J; Schwartz S; Lo J; Ojo A; Sondheimer J; Hsu CY; Lash J; Leonard M; Kusek JW; Feldman HI; Wolf M;
JAMA; 2011 Jun; 305(23):2432-9. PubMed ID: 21673295
[TBL] [Abstract][Full Text] [Related]
4. Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function.
Wang M; You L; Li H; Lin Y; Zhang Z; Hao C; Chen J
Clin J Am Soc Nephrol; 2013 Jan; 8(1):116-25. PubMed ID: 23085728
[TBL] [Abstract][Full Text] [Related]
5. Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.
Edmonston D; Wojdyla D; Mehta R; Cai X; Lora C; Cohen D; Townsend RR; He J; Go AS; Kusek J; Weir MR; Isakova T; Pencina M; Wolf M;
Am J Kidney Dis; 2019 Dec; 74(6):771-781. PubMed ID: 31445926
[TBL] [Abstract][Full Text] [Related]
6. Mild hyperphosphatemia and mortality in hemodialysis patients.
Rodriguez-Benot A; Martin-Malo A; Alvarez-Lara MA; Rodriguez M; Aljama P
Am J Kidney Dis; 2005 Jul; 46(1):68-77. PubMed ID: 15983959
[TBL] [Abstract][Full Text] [Related]
7. FGF-23 in patients with end-stage renal disease on hemodialysis.
Imanishi Y; Inaba M; Nakatsuka K; Nagasue K; Okuno S; Yoshihara A; Miura M; Miyauchi A; Kobayashi K; Miki T; Shoji T; Ishimura E; Nishizawa Y
Kidney Int; 2004 May; 65(5):1943-6. PubMed ID: 15086938
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of FGF-23 measurement in dialysis patients.
Jongbloed F; Galassi A; Cozzolino M; Zietse R; Chiarelli G; Cusi D; Brancaccio D; Gallieni M
Clin Nephrol; 2011 Sep; 76(3):201-9. PubMed ID: 21888857
[TBL] [Abstract][Full Text] [Related]
9. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.
Kendrick J; Cheung AK; Kaufman JS; Greene T; Roberts WL; Smits G; Chonchol M;
J Am Soc Nephrol; 2011 Oct; 22(10):1913-22. PubMed ID: 21903574
[TBL] [Abstract][Full Text] [Related]
10. The impact of high serum bicarbonate levels on mortality in hemodialysis patients.
Chang KY; Kim HW; Kim WJ; Kim YK; Kim SH; Song HC; Kim YO; Jin DC; Choi EJ; Yang CW; Kim YL; Kim NH; Kang SW; Kim YS; Kim YS
Korean J Intern Med; 2017 Jan; 32(1):109-116. PubMed ID: 27044857
[TBL] [Abstract][Full Text] [Related]
11. The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients.
Park SY; Jeong KH; Moon JY; Lee SH; Ihm CG; Rhee SY; Woo JT; Oh IH; Lee TW
Clin Exp Nephrol; 2010 Jun; 14(3):239-43. PubMed ID: 20376517
[TBL] [Abstract][Full Text] [Related]
12. Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-Mineral and bone disorder with all-cause mortality in South African patients on maintenance dialysis: A 3-year prospective cohort study.
Waziri B; Musenge E; Duarte R; Dickens C; Dix-Peek T; Rekhviashvili V; Paget G; Naicker S
PLoS One; 2019; 14(5):e0216656. PubMed ID: 31107896
[TBL] [Abstract][Full Text] [Related]
13. Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.
Kalim S; Tamez H; Wenger J; Ankers E; Trottier CA; Deferio JJ; Berg AH; Karumanchi SA; Thadhani RI
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1927-34. PubMed ID: 23970130
[TBL] [Abstract][Full Text] [Related]
14. Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.
Scialla JJ; Parekh RS; Eustace JA; Astor BC; Plantinga L; Jaar BG; Shafi T; Coresh J; Powe NR; Melamed ML
Am J Nephrol; 2015; 42(1):25-34. PubMed ID: 26287973
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
[TBL] [Abstract][Full Text] [Related]
16. FGF-23 levels in patients with AKI and risk of adverse outcomes.
Leaf DE; Wolf M; Waikar SS; Chase H; Christov M; Cremers S; Stern L
Clin J Am Soc Nephrol; 2012 Aug; 7(8):1217-23. PubMed ID: 22700885
[TBL] [Abstract][Full Text] [Related]
17. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients.
Unver S; Kavlak E; Gümüsel HK; Celikbilek F; Esertas K; Muftuoglu T; Kirilmaz A
Ren Fail; 2015 Jul; 37(6):951-6. PubMed ID: 26030798
[TBL] [Abstract][Full Text] [Related]
18. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease.
Negri AL
Int Urol Nephrol; 2014 Jan; 46(1):9-17. PubMed ID: 23296792
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
